NO20070917L - Imidazotriaziner som protein-kinaseinhibitorer - Google Patents
Imidazotriaziner som protein-kinaseinhibitorerInfo
- Publication number
- NO20070917L NO20070917L NO20070917A NO20070917A NO20070917L NO 20070917 L NO20070917 L NO 20070917L NO 20070917 A NO20070917 A NO 20070917A NO 20070917 A NO20070917 A NO 20070917A NO 20070917 L NO20070917 L NO 20070917L
- Authority
- NO
- Norway
- Prior art keywords
- imidazotriazines
- protein kinase
- kinase inhibitors
- treatment
- igf1r
- Prior art date
Links
- XZLIYCQRASOFQM-UHFFFAOYSA-N 5h-imidazo[4,5-d]triazine Chemical class N1=NC=C2NC=NC2=N1 XZLIYCQRASOFQM-UHFFFAOYSA-N 0.000 title 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 abstract 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58951404P | 2004-07-20 | 2004-07-20 | |
PCT/US2005/025891 WO2006012422A1 (fr) | 2004-07-20 | 2005-07-20 | Imidazotriazines comme inhibiteurs de la tyrosine kinase |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20070917L true NO20070917L (no) | 2007-03-19 |
Family
ID=35482337
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20070917A NO20070917L (no) | 2004-07-20 | 2007-02-16 | Imidazotriaziner som protein-kinaseinhibitorer |
Country Status (18)
Country | Link |
---|---|
US (1) | US7741324B2 (fr) |
EP (1) | EP1781660A1 (fr) |
JP (1) | JP4918038B2 (fr) |
KR (1) | KR20070035087A (fr) |
CN (1) | CN101084218A (fr) |
AP (1) | AP2007003924A0 (fr) |
AR (1) | AR053090A1 (fr) |
AU (1) | AU2005267120B2 (fr) |
BR (1) | BRPI0513565A (fr) |
CA (1) | CA2574594A1 (fr) |
EA (1) | EA200700220A1 (fr) |
IL (1) | IL180806A0 (fr) |
MX (1) | MX2007000822A (fr) |
MY (1) | MY139689A (fr) |
NO (1) | NO20070917L (fr) |
RU (1) | RU2007106068A (fr) |
TW (1) | TW200613306A (fr) |
WO (1) | WO2006012422A1 (fr) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7026500B2 (en) * | 2000-08-24 | 2006-04-11 | University Of Tennessee Research Foundation | Halogenated selective androgen receptor modulators and methods of use thereof |
ATE433979T1 (de) | 2004-04-02 | 2009-07-15 | Osi Pharm Inc | Mit einem 6,6-bicyclischen ring substituierte heterobicyclische proteinkinaseinhibitoren |
PL2385053T3 (pl) * | 2005-11-17 | 2014-05-30 | Osi Pharmaceuticals Llc | Związki pośrednie do wytwarzania skondensowanych bicyklicznych inhibitorów mTOR |
US8575164B2 (en) * | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
EP1981890A2 (fr) * | 2006-01-25 | 2008-10-22 | OSI Pharmaceuticals, Inc. | INHIBITEURS DE mTOR INSATURES |
WO2008121742A2 (fr) * | 2007-03-28 | 2008-10-09 | Pharmacyclics, Inc. | Inhibiteurs de la tyrosine kinase de bruton |
WO2008064157A1 (fr) | 2006-11-22 | 2008-05-29 | Incyte Corporation | Imidazotriazines et imidazopyrimidines utilisées en tant qu'inhibiteurs de kinases |
US20120101113A1 (en) | 2007-03-28 | 2012-04-26 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
EP2145205B1 (fr) * | 2007-05-01 | 2019-09-18 | QUALCOMM Incorporated | Emplacement de position pour systèmes de communication sans fil |
US8130700B2 (en) | 2007-06-15 | 2012-03-06 | Silver Spring Networks, Inc. | Method and system for providing network and routing protocols for utility services |
WO2009091939A1 (fr) * | 2008-01-18 | 2009-07-23 | Osi Pharmaceuticals, Inc. | Dérivés d'imidazopyrazinol pour le traitement des cancers |
KR20110017845A (ko) * | 2008-03-19 | 2011-02-22 | 오에스아이 파마슈티컬스, 인코포레이티드 | Mtor 억제자 염 형태 |
EP2283020B8 (fr) * | 2008-05-19 | 2012-12-12 | OSI Pharmaceuticals, LLC | Imidazopyrazines et imidazotriazines substituées |
EP3287449A3 (fr) * | 2008-05-21 | 2018-05-30 | Incyte Holdings Corporation | Sels de 2-fluoro-n-méthyl-4-[7-(quinolin-6-yl-méthyl) - imidazo [1,2-b] [1,2,4] triazin-2-yl] benzamide et procédés associés à leur préparation |
EP2313102A2 (fr) | 2008-07-03 | 2011-04-27 | Biota Scientific Management | Nucléosides bicycliques et nucléotides convenant comme agents thérapeutiques |
DE102009005193A1 (de) * | 2009-01-20 | 2010-07-22 | Merck Patent Gmbh | Neue heterocyclische Verbindungen als MetAP-2 Inhibitoren |
WO2010123792A1 (fr) | 2009-04-20 | 2010-10-28 | Osi Pharmaceuticals, Inc. | Préparation de c-pyrazine-méthylamines |
WO2010129740A1 (fr) * | 2009-05-07 | 2010-11-11 | Osi Pharmaceuticals, Inc. | Utilisation d'osi-906 dans le traitement du carcinome adrénocortical |
EP2531509B1 (fr) * | 2010-02-03 | 2016-10-05 | Incyte Holdings Corporation | Imidazo[1,2-b][1,2,4]triazines en tant qu'inhibiteurs de c met |
JP2013522215A (ja) | 2010-03-09 | 2013-06-13 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 組合わせ抗癌療法 |
MX2020004501A (es) | 2010-06-03 | 2021-11-09 | Pharmacyclics Llc | El uso de inhibidores de la tirosina quinasa de bruton (btk). |
MX2013008833A (es) | 2011-02-02 | 2013-12-06 | Amgen Inc | Metodos y composiciones relacionadas con la inhibicion de receptor del factor de crecimiento similar a la insulina 1 (igf-1r). |
JP5543039B2 (ja) | 2011-02-23 | 2014-07-09 | ファイザー・インク | 神経障害治療のためのイミダゾ[5,1−f][1,2,4]トリアジン |
EA201490265A1 (ru) | 2011-07-13 | 2014-12-30 | Фармасайкликс, Инк. | Ингибиторы тирозинкиназы брутона |
ES2723827T3 (es) | 2011-11-11 | 2019-09-02 | Univ Duke | Terapia de combinación de fármacos para el tratamiento de tumores sólidos |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
CN107082783B (zh) | 2012-01-26 | 2019-03-22 | H.隆德贝克有限公司 | 具有咪唑并三嗪酮骨架的pde9抑制剂 |
CN103374001B (zh) * | 2012-04-19 | 2015-10-28 | 山东轩竹医药科技有限公司 | 咪唑并三嗪类mTOR抑制剂 |
CA3218491A1 (fr) | 2012-06-04 | 2013-12-12 | Pharmacyclics Llc | Formes cristallines d'un inhibiteur de tyrosine kinase de bruton |
US8980259B2 (en) | 2012-07-20 | 2015-03-17 | Novartis Ag | Combination therapy |
BR112015001690A2 (pt) | 2012-07-24 | 2017-11-07 | Pharmacyclics Inc | mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk) |
BR112015011171A2 (pt) | 2012-11-15 | 2017-07-11 | Pharmacyclics Inc | compostos de pirrolopirimidina como inibidores da quinase |
TN2016000094A1 (en) | 2013-09-30 | 2017-07-05 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase. |
WO2015058084A1 (fr) * | 2013-10-18 | 2015-04-23 | Medivation Technologies, Inc. | Composés hétérocycliques et procédés d'utilisation |
WO2015081783A1 (fr) * | 2013-12-06 | 2015-06-11 | 江苏奥赛康药业股份有限公司 | Dérivé de pyrrolo[2,1-f][1,2,4]triazine, son procédé de préparation et utilisation |
US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
EP3174539A4 (fr) | 2014-08-01 | 2017-12-13 | Pharmacyclics, LLC | Inhibiteurs de la tyrosine kinase de bruton |
WO2016022942A1 (fr) | 2014-08-07 | 2016-02-11 | Pharmacyclics Llc | Nouvelles formulations d'un inhibiteur de la tyrosine kinase de bruton |
AU2016226279B2 (en) | 2015-03-03 | 2021-11-11 | Pharmacyclics Llc | Pharmaceutical formulations of Bruton's tyrosine kinase inhibtor |
AU2016289856B2 (en) | 2015-07-07 | 2020-11-26 | H. Lundbeck A/S | PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases |
WO2017035366A1 (fr) | 2015-08-26 | 2017-03-02 | Incyte Corporation | Dérivés de type pyrrolo-pyrimidine utilisés comme inhibiteurs des tam |
WO2017129763A1 (fr) | 2016-01-28 | 2017-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes et compositions pharmaceutiques pour le traitement du cancer de l'estomac à cellules en bague à chaton |
RS65129B1 (sr) * | 2016-03-28 | 2024-02-29 | Incyte Corp | Jedinjenja pirolotriazina kao inhibitori tam |
EP3548046A2 (fr) * | 2016-12-03 | 2019-10-09 | Juno Therapeutics, Inc. | Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase |
WO2019067594A1 (fr) | 2017-09-27 | 2019-04-04 | Incyte Corporation | Sels de dérivés de pyrrolotriazine utiles en tant qu'inhibiteurs de tam |
PE20211805A1 (es) | 2018-06-29 | 2021-09-14 | Incyte Corp | Formulaciones de un inhibidor de axl/mer |
WO2023196975A1 (fr) * | 2022-04-08 | 2023-10-12 | Shy Therapeutics, Llc | Composés interagissant avec des protéines de la superfamille ras pour le traitement de cancers, de maladies inflammatoires, de rasopathies et d'une maladie fibrotique |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5217999A (en) | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
DE69105495T2 (de) | 1990-04-02 | 1995-04-06 | Pfizer | Benzylphosphonsäure-tyrosinkinaseinhibitoren. |
US5302606A (en) | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
US6645969B1 (en) | 1991-05-10 | 2003-11-11 | Aventis Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
CA2102780C (fr) | 1991-05-10 | 2007-01-09 | Alfred P. Spada | Composes de type bis-monoaryle, aryle bicyclique et (ou) heteroaryle inhibant l'activite de tyrosine kinase des recepteurs de l'egf et (ou) du pdgf |
WO1992021660A1 (fr) | 1991-05-29 | 1992-12-10 | Pfizer, Inc. | Composes tricycliques polyhydroxyliques inhibiteurs de la tyrosine-kinase |
MX9304801A (es) | 1992-08-06 | 1997-06-28 | Warner Lambert Co | 2-toindoles (selenoidoles) disulfuros (seleniduros) relacinados, los cuales inhiben a las proteinas tirosina cinasas y los cuales tienen propiedades anti-tumorales. |
SK283413B6 (sk) | 1992-08-06 | 2003-07-01 | Warner-Lambert Company | 2-Tioindoly, 2-indolíntióny a polysulfidy, ich selénové analógy a farmaceutické prostriedky na ich báze |
GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
JPH07133280A (ja) | 1993-11-09 | 1995-05-23 | Takeda Chem Ind Ltd | セフェム化合物、その製造法および抗菌組成物 |
US5584409A (en) * | 1995-09-18 | 1996-12-17 | Chemberlen; Christopher H. | One direction ventilation valves |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
CH690773A5 (de) | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo(2,3-d)pyrimide und ihre Verwendung. |
US6514971B1 (en) | 1996-03-15 | 2003-02-04 | Zeneca Limited | Cinnoline derivatives and use as medicine |
KR20000065171A (ko) | 1996-05-01 | 2000-11-06 | 피터 지. 스트링거 | 혈관내피세포성장인자관련질병의치료방법 |
US6232299B1 (en) | 1996-05-01 | 2001-05-15 | Eli Lilly And Company | Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy |
UA54427C2 (uk) | 1996-05-01 | 2003-03-17 | Елі Ліллі Енд Компані | Спосіб лікування очних захворювань, які пов'язані з фактором васкулярного ендотеліального росту |
GB9707800D0 (en) | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
KR20010085824A (ko) | 1998-09-18 | 2001-09-07 | 스타르크, 카르크 | 단백질 키나아제 억제제로서의 피롤로피리미딘 |
WO2000035455A1 (fr) | 1998-12-15 | 2000-06-22 | Telik, Inc. | Urees heteroaryle-aryle utilisees comme antagonistes du recepteur igf-1 |
US6982265B1 (en) | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
DE60042620D1 (de) | 1999-05-21 | 2009-09-03 | Bristol Myers Squibb Co | Pyrrolotriazine als Kinase Hemmer. |
AU2000240570A1 (en) * | 2000-03-29 | 2001-10-08 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
MXPA03008560A (es) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
TWI238824B (en) | 2001-05-14 | 2005-09-01 | Novartis Ag | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives |
SE0102168D0 (sv) | 2001-06-19 | 2001-06-19 | Karolinska Innovations Ab | New use and new compounds |
JP3933420B2 (ja) * | 2001-07-24 | 2007-06-20 | 出光ユニテック株式会社 | 収納袋の排気弁 |
US7115617B2 (en) | 2001-08-22 | 2006-10-03 | Amgen Inc. | Amino-substituted pyrimidinyl derivatives and methods of use |
US6939874B2 (en) | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
GB0122560D0 (en) | 2001-09-19 | 2001-11-07 | Aventis Pharma Ltd | Chemical compounds |
HUP0401982A3 (en) | 2001-09-19 | 2012-09-28 | Aventis Pharma Sa | Indolizine derivates, process for their preparation and pharmaceutical compositions containing the compounds |
US6827492B2 (en) * | 2001-12-05 | 2004-12-07 | Leland B. Cook | One-way concealed-valve vented storage bag |
SE0104140D0 (sv) | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
US20050215564A1 (en) | 2002-02-14 | 2005-09-29 | Stiles Charles D | Methods and compositions for treating hyperproliferative conditions |
EP1476192B1 (fr) | 2002-02-14 | 2007-04-25 | Dana-Farber Cancer Institute, Inc. | Procedes et compositions pour traiter des etats hyperproliferatifs |
DE10230605A1 (de) | 2002-07-08 | 2004-01-29 | Bayer Ag | Substituierte Imidazotriazine |
DE10230604A1 (de) | 2002-07-08 | 2004-01-29 | Bayer Ag | Heterocyclisch substituierte Imidazotriazine |
UA80171C2 (en) | 2002-12-19 | 2007-08-27 | Pfizer Prod Inc | Pyrrolopyrimidine derivatives |
BRPI0408248A (pt) | 2003-03-12 | 2006-03-01 | Pfizer Prod Inc | derivados azabicìclicos de piridiloximetila e de benzisoxazol |
ATE433979T1 (de) * | 2004-04-02 | 2009-07-15 | Osi Pharm Inc | Mit einem 6,6-bicyclischen ring substituierte heterobicyclische proteinkinaseinhibitoren |
-
2005
- 2005-07-19 MY MYPI20053287A patent/MY139689A/en unknown
- 2005-07-19 AR ARP050102978A patent/AR053090A1/es not_active Application Discontinuation
- 2005-07-19 TW TW094124340A patent/TW200613306A/zh unknown
- 2005-07-20 EP EP05773226A patent/EP1781660A1/fr not_active Withdrawn
- 2005-07-20 EA EA200700220A patent/EA200700220A1/ru unknown
- 2005-07-20 AU AU2005267120A patent/AU2005267120B2/en not_active Ceased
- 2005-07-20 CA CA002574594A patent/CA2574594A1/fr not_active Abandoned
- 2005-07-20 KR KR1020077003827A patent/KR20070035087A/ko not_active Application Discontinuation
- 2005-07-20 JP JP2007522756A patent/JP4918038B2/ja not_active Expired - Fee Related
- 2005-07-20 US US11/185,599 patent/US7741324B2/en not_active Expired - Fee Related
- 2005-07-20 AP AP2007003924A patent/AP2007003924A0/xx unknown
- 2005-07-20 WO PCT/US2005/025891 patent/WO2006012422A1/fr active Application Filing
- 2005-07-20 CN CNA2005800317167A patent/CN101084218A/zh active Pending
- 2005-07-20 BR BRPI0513565-6A patent/BRPI0513565A/pt not_active IP Right Cessation
- 2005-07-20 MX MX2007000822A patent/MX2007000822A/es active IP Right Grant
- 2005-07-20 RU RU2007106068/04A patent/RU2007106068A/ru not_active Application Discontinuation
-
2007
- 2007-01-18 IL IL180806A patent/IL180806A0/en unknown
- 2007-02-16 NO NO20070917A patent/NO20070917L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2006012422A1 (fr) | 2006-02-02 |
CN101084218A (zh) | 2007-12-05 |
AR053090A1 (es) | 2007-04-25 |
IL180806A0 (en) | 2007-06-03 |
JP4918038B2 (ja) | 2012-04-18 |
MY139689A (en) | 2009-10-30 |
JP2008507546A (ja) | 2008-03-13 |
US7741324B2 (en) | 2010-06-22 |
AU2005267120B2 (en) | 2011-06-02 |
KR20070035087A (ko) | 2007-03-29 |
BRPI0513565A (pt) | 2008-05-06 |
AP2007003924A0 (en) | 2007-02-28 |
TW200613306A (en) | 2006-05-01 |
US20060019957A1 (en) | 2006-01-26 |
EA200700220A1 (ru) | 2007-08-31 |
AU2005267120A1 (en) | 2006-02-02 |
EP1781660A1 (fr) | 2007-05-09 |
CA2574594A1 (fr) | 2006-02-02 |
RU2007106068A (ru) | 2008-08-27 |
MX2007000822A (es) | 2007-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20070917L (no) | Imidazotriaziner som protein-kinaseinhibitorer | |
NO20062136L (no) | Imidazopyrazintyrosin-kinaseinhibitorer | |
NO20065727L (no) | Pyrrolinhibitorer av erk-proteinkinase, syntese derav og deres mellomprodukter | |
NO20064895L (no) | 6,6-Bisykliske ring-substituerte heterobisykliske protein-kinase inhibitorer | |
NO20082508L (no) | Aminopyrimidiner anvendelige som kinaseinhibitorer | |
NO20083918L (no) | Dihydridiazepiner anvendelige som inhibitorer av proteinkinaser | |
NO20073140L (no) | Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser | |
HK1135103A1 (en) | Dihydropyridine derivatives useful as protein kinase inhibitors | |
NO20076093L (no) | Substituerte amidderivater som proteinkinaseinhibitorer | |
NO20080675L (no) | P38-Map kinaseinhibitorer og metoder for deres anvendelse | |
NO20084747L (no) | Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser | |
DK1791830T3 (da) | Diaminotriazol-forbindelser der er nyttige som protein-kinase-inhibitorer | |
WO2008094992A3 (fr) | Inhibiteurs de kinase | |
EA200870373A1 (ru) | Пиридил- и пиримидинилзамещённые производные пиррола, тиофена и фурана в качестве ингибиторов киназ | |
NO20082026L (no) | Deazapuriner som er nyttige som inhibitorer for Janus-kinaser | |
NO20084418L (no) | Azolopyridin-3-on derivater som inhibitorer av endoteliallipase | |
SG170828A1 (en) | Deazapurines useful as inhibitors of janus kinases | |
NO20072747L (no) | Fremgangsmate for fremstilling av indazolforbindelser | |
NO20076659L (no) | Pyrrolo(2,3-B)pyridinderivater som protein kinase inhibitorer | |
WO2007087283A3 (fr) | Thiophene-carboxamides utiles en tant qu'inhibiteurs de proteines kinases | |
NO20062763L (no) | Pyrrolotriazinforbindelser som kinaseinhibitorer | |
MX2009009590A (es) | Aminopirimidinas utiles como inhibidores de proteinas cinasas. | |
MX2009004716A (es) | Compuestos y composiciones en la forma de inhibidores de quinasa de proteina. | |
NO20084435L (no) | C-MET proteinkinaseinhibitorer | |
NO20070453L (no) | Kondenserte heterocykliske kinase inhibitorer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |